GERAGHTY JAMES A 4

What Happened

• James A. Geraghty, a director of Voyager Therapeutics, was granted a derivative award on 2026-06-09 covering 30,000 shares (stock option). The reported price is $0.00, indicating a grant/award rather than an open‑market purchase or sale. No cash value or exercise price is disclosed in the filing.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (appears timely).
• Transaction code: A (award/grant of a derivative security).
• Shares/options granted: 30,000 (derivative — stock option).
• Reported price: $0.00 (grant).
• Shares owned after transaction: not specified in the filing.
• Footnote: The option was issued under Voyager’s 2025 Stock Incentive Plan per the company’s director compensation policy. Vesting commencement date = grant date. All underlying shares vest upon the earlier of (a) the one‑year anniversary of the grant or (b) the next annual meeting of stockholders, in each case subject to continued service as a director.
• Exhibit noted: Exhibit 24 — Power of Attorney.

Context

• This filing documents an award of stock options to a director as part of routine director compensation; it is not an exercise or sale and does not represent immediate market activity (no shares sold or purchased on the open market).
• For retail investors: awards signal compensation alignment but are common and should not be interpreted alone as a buy/sell signal.